The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
The French firm said that the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products.
In Science this week: DNA Fountain for storing data in DNA, and more.
Researchers in the US and Ukraine built a microRNA-based classifier to categorize infants as affected or unaffected.
Through the acquisition, Miroculus will be able to automate and simplify the detection of miRNAs from blood using Kapplex's digital microfluidic technology.
The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The company plans to establish a clinical laboratory to offer its Gensignia miRNA Signature Classifier for Lung Cancer Test, as well as other tests in the future.
Prolias accused PDI of breaching a joint venture agreement to validate, commercialize, and monetize Prolias' miRNA thyroid cancer test. PDI denied liability and said it would defend itself vigorously.
The investment bank upgraded Rosetta's shares following the completion of the firm's purchase of PersonalizeDx earlier in the week.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.